Paratope Bio is developing targeted immuno-oncology therapies that utilize innate antibodies to create less toxic cancer treatments. This approach aims to reduce the adverse effects associated with traditional cancer therapies while enhancing treatment efficacy.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer therapies often have significant toxic side effects due to their non-specific targeting of both cancerous and healthy cells. This lack of specificity can lead to severe adverse reactions, limiting the dosage and effectiveness of treatment.
Solution
Paratope Bio is engineering targeted immuno-oncology therapies based on innate antibodies to improve cancer treatment outcomes while minimizing toxicity. By harnessing the specificity of innate antibodies, their approach aims to selectively target and eliminate cancer cells, sparing healthy tissues from damage. This targeted approach has the potential to reduce the debilitating side effects associated with conventional chemotherapy and radiation, leading to improved patient quality of life and treatment adherence.
Target Audience
The primary target audience includes cancer patients seeking less toxic treatment options and oncologists looking for more targeted and effective therapies.
Features
- Targeted immuno-oncology therapies
- Utilizes innate antibodies for enhanced specificity
- Designed to minimize toxic side effects